---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-039291"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:20:05.331517+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BiomX Q1 net loss $6.4M; cash $30.3M; positive Part 1 BX004 data; PIPE closed

## Summary
- Net loss $6.4M vs $8.2M YoY; R&D expense $4.6M; cash $30.3M as of March 31, 2023.
- Positive Phase 1b/2a Part 1 BX004 results: >90% reduction in P. aeruginosa CFU; no safety events; Part 2 data expected Q3 2023.
- Completed $7.5M PIPE with OrbiMed and CF Foundation; second closing in May 2023.
- Jason M. Marks and Michael E. Dambach appointed to Board of Directors.
- Cash runway sufficient into Q3 2024.

## SEC filing metadata
- accession: 0001213900-23-039291
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/0001213900-23-039291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/ea178578-8k_biomxinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-039291
- JSON: https://secwatch.observer/filing/0001213900-23-039291.json
- Plain text: https://secwatch.observer/filing/0001213900-23-039291.txt

## Key facts
- Executive change
  Michael E. Dambach was appointed as Class II Director at BiomX Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/0001213900-23-039291-index.htm
- Executive change
  Jason M. Marks was appointed as Class II Director at BiomX Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/0001213900-23-039291-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.